Characteristics and Mortality Among Hospitalized Patients Treated with Intramuscular Antipsychotics: Analysis of a United States Hospital Database

Author(s): Karen C. Holdridge, Sebastian Sorsaburu, John P. Houston, William Saunders.

Journal Name: Current Drug Safety

Volume 5 , Issue 3 , 2010

Become EABM
Become Reviewer


Mortality rates across matched cohorts of hospitalized patients treated with IM olanzapine, haloperidol, and/or ziprasidone in a hospital database were compared. Using propensity score matching, matched cohorts of IM olanzapine- (N=2,984) and IM haloperidol-treated patients (N=2,984) and IM olanzapine- (N=2,876) and IM ziprasidone-treated patients (N=2,876) were obtained. The study outcome was in-hospital death within 2 days of administering IM antipsychotic. Incidence of death was not statistically different between olanzapine-ziprasidone cohorts (OR=1.21, 95% CI 0.92-1.59). The olanzapine cohort demonstrated a significantly lower death incidence than the haloperidol cohort (OR=0.73, 95% CI 0.57-0.93; p=.011). The results suggest that patients treated with IM olanzapine do not have a significantly greater risk of death than patients treated with IM haloperidol or IM ziprasidone.

Keywords: Olanzapine, ziprasidone, haloperidol, hospital database, agitation, mortality

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [203 - 211]
Pages: 9
DOI: 10.2174/157488610791698262
Price: $58

Article Metrics

PDF: 3